Background This study aimed to better characterize the clinicopathologic characteristics, outcomes, and prognostic factors of AITL in China. Methods We retrospectively analyzed 312 patients with AITL enrolled between January 2011 and December 2020 from five institutions in China. Results The median age was 65 years, with 92.6% advanced stage, 59.7% elevated LDH, 46.1% anemia, and 44.0% hypergammaglobulinemia. The majority of patients (84.9%) received anthracycline‐based regimens with or without etoposide, and only 6.1% underwent autologous stem cell transplantation following first remission. The 5‐year OS and PFS estimates were 43.4% and 25.0% with no significant improvement of survival between patients treated during 2011–2015 and 2016–2020, respectively. Both the International Prognostic Index (IPI) and the prognostic index for PTCL, not otherwise specified (PIT), were predictive for OS. In multivariate analysis, age >70 years, elevated LDH, and albumin level <35 g/L were independent prognostic factors for OS. Combining these three factors, a novel prognostic model (the Chinese AITL score) was constructed, which stratified patients into low‐, intermediate‐, and high‐risk groups, with 5‐year OS rates of 69.0%, 41.5%, and 23.7%, respectively. This new model was successfully validated in an independent cohort. Conclusions Patients with AITL were mainly treated with anthracycline‐based regimens, and the outcomes were still unsatisfactory in China. Our novel prognostic model may improve our ability to identify patients at different risks for alternative therapies.

No abstract

No abstract